Xu, Binghe http://orcid.org/0000-0003-4195-337X
Sun, Tao
Shi, Yanxia
Cui, Jiuwei
Yin, Yongmei
Ouyang, Quchang
Liu, Qiang
Zhang, Qingyuan
Chen, Yiding
Wang, Shouman
Wang, Xiaojia
Tong, Zhongsheng
Zhong, Yahua
Wang, Jiayu
Yan, Min
Yan, Xi
Wang, Chuan
Feng, Jifeng
Wang, Xiuli
Hu, Gang
Cheng, Ying
Ge, Ruimin
Zhu, Zhaoyin
Zhang, Wa
Shao, Zhimin
Clinical trials referenced in this document:
Documents that mention this clinical trial
Pamiparib in patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutations: a phase II study
https://doi.org/10.1007/s10549-022-06785-z
Funding for this research was provided by:
BeiGene, Ltd.
Article History
Received: 18 May 2022
Accepted: 24 October 2022
First Online: 2 December 2022
Declarations
:
: Binghe Xu reports receiving advisory fees from Novartis and Roche, and fees for serving on a speakers’ bureau from AstraZeneca, Pfizer, Roche, and Eisai. Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin, Quchang Ouyang, Qiang Liu, Qingyuan Zhang, Yiding Chen, Shouman Wang, Xiaojia Wang, Zhongsheng Tong, Yahua Zhong, Jiayu Wang, Min Yan, Xi Yan, Chuan Wang, Jifeng Feng, Xiuli Wang, Gang Hu, Ying Cheng, and Zhimin Shao have no relevant financial or non-financial interests to disclose. Ruimin Ge, Zhaoyin Zhu, and Wa Zhang are employees of BeiGene, Ltd., and have no competing interests.